Kempharm, inc (KMPH)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Revenue

12,839

0

-

-

-

-

-

Revenue

-

-

-

0

0

0

0

Operating expenses:
Royalty and direct contract acquisition costs

2,945

-

-

-

-

-

-

Research and development

19,415

41,759

20,593

20,472

13,931

11,917

3,367

General and administrative

10,816

12,508

12,773

14,000

8,883

4,526

1,351

Severance expense

-

1,636

-

3,010

0

0

-

Total operating expenses

33,176

55,903

-

-

-

-

-

Total operating expenses

-

-

33,366

37,482

22,814

16,443

4,718

Loss from operations

-20,337

-55,903

-33,366

-37,482

-22,814

-16,443

-4,718

Other (expense) income:
Gain on extinguishment of debt

-

2

-

-4,740

0

1,900

-

Interest expense related to amortization of debt issuance costs and discount

1,656

1,618

1,561

1,616

1,909

1,114

1,560

Interest expense on principal

4,858

5,469

5,776

5,511

2,671

1,605

157

Fair value adjustment related to derivative and warrant liability

-1,998

-5,976

3,091

-32,465

27,276

7,223

-1,137

Interest and other income, net

309

420

365

353

32

8

52

Total other (expense) income

-4,207

-689

-10,063

20,951

-31,824

-8,034

-528

Loss before income taxes

-24,544

-56,592

-43,429

-16,531

-54,638

-24,477

-5,246

Income tax benefit

-22

-126

-43

-15

26

-22

-20

Net loss

-24,522

-56,466

-43,386

-16,516

-54,664

-24,455

-5,226

Net loss per share of common stock:
Basic and diluted (in dollars per share)

-0.83

-3.15

-2.96

-1.13

-7.42

-10.27

-2.20

Weighted average number of shares of common stock outstanding:
Basic and diluted (in shares)

29,654

17,930

14,652

14,597

7,368

2,381

2,381